Communication of the meeting of Transparency Council No. 10/2026 on 9 March with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 10/2026 on 9 March 2026 during which the following resolutions were adopted:

1. At its meeting on 9 March 2026, the Transparency Council adopted position No. 30/2026 regarding the evaluation of the drug Kinpeygo (budesonide) under drug program B.171, “Treatment of patients with primary IgA nephropathy (ICD-10: N02.8)”
2. At its meeting on 9 March 2026, the Transparency Council adopted opinion No. 29/2026 on the draft program “Program for the Prevention of RSV Infections Among Poznań Residents Aged 60–64 for the Years 2026–2028”
3. At its meeting on 9 March 2026, the Transparency Council adopted opinion No. 30/2026 on the draft program “Program for the Prevention of Shingles and Postherpetic Neuralgia Among Poznań Residents Aged 60–64 for the Years 2026–2028”
4. At its meeting on 9 March 2026, the Transparency Council adopted opinion No. 31/2026 regarding the inclusion of medicinal products containing the active ingredient cyproterone in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, namely transsexualism (ICD-10: F64.0)
5. At its meeting on 9 March 2026, the Transparency Council adopted opinion No. 32/2026 regarding the inclusion of medicinal products containing the active ingredient estradiolum in the reimbursement program for indications, dosages, or routes of administration other than those specified in the Summary of Product Characteristics, namely transsexualism (ICD-10: F64.0)

Transparency Council meeting protocol >>